Legend Biotech Corporation - American Depositary Shares (NQ:LEGN)

18.57 UNCHANGED

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Legend Biotech Corporation - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9

...

12 13 Next >

LEGN Stock Earnings: Legend Biotech Beats EPS, Beats Revenue for Q2 2024 ↗

August 09, 2024

LEGN stock results show that Legend Biotech beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.

Via InvestorPlace

Legend Biotech Reports Second Quarter 2024 Results and Recent Highlights

August 09, 2024

From Legend Biotech USA Inc.

Via GlobeNewswire

Legend Biotech Appoints Peter Salovey, Ph.D., to its Board of Directors

August 08, 2024

From Legend Biotech USA Inc.

Via GlobeNewswire

Will Genscript Cash Out Of Legend Biotech In The Face Of Fat Profit Temptation? ↗

August 01, 2024

Key Takeaways: Analysts expect annual sales of Carvykti, Legend Biotech’s core cancer therapy, to peak at $7.3 billion With about $2 billion in cash reserves, Genscript isn’t under pressure to sell its...

Via Benzinga

The Latest Analyst Ratings For Legend Biotech ↗

July 15, 2024

Via Benzinga

Assessing Legend Biotech: Insights From 15 Financial Analysts ↗

June 21, 2024

Via Benzinga

Unveiling 18 Analyst Insights On Legend Biotech ↗

June 04, 2024

Via Benzinga

Legend Biotech Stock: A Deep Dive Into Analyst Perspectives (14 Ratings) ↗

May 14, 2024

Via Benzinga

Legend Biotech Announces Preliminary Results for the Six-Months Ended June 30, 2024

July 26, 2024

From Legend Biotech USA Inc.

Via GlobeNewswire

Warner Bros. Discovery & Coinbase Are Among 10 Large Cap Stocks That Shined Most Last Week (July 14-July 20): Are The Others In Your Portfolio? ↗

July 21, 2024

Top performers last week: $WBD up 18.28%, $MSTR up 16.74%, $DHI up 12.91%, $COIN up 12.39%, $OQL up 7.89%, $UNH up 7.84%, $STT up 7.21%, $LEN up 7.07%, $TOST up 7.05%, $EPAM up 6.97%. Are they in your...

Via Benzinga

Week In Review: Korea's SK Biopharma Acquires Radiopharmaceutical In $571 Million Deal ↗

July 20, 2024

In recent news, South Korea’s SK Biopharma in-licensed global rights to a radiopharmaceutical compound developed by Full-Life Technologies of Shanghai in a $571 million deal.

Via Talk Markets

Cintas Posts Upbeat Earnings, Joins CommScope Holding, Virtu Financial And Other Big Stocks Moving Higher On Thursday ↗

July 18, 2024

Via Benzinga

Analyst Ratings For Legend Biotech ↗

April 17, 2024

Via Benzinga

CPI Data Sparks Rally in Biotech Stocks

July 15, 2024

Following lower-than-expected inflation data on Thursday, The biotech sector broke out above resistance, closing the week up 6%, far outperforming the market.

Via MarketBeat

Topics ETFs Economy

Legend Biotech to Host Investor Conference Call on Second Quarter 2024 Results

July 10, 2024

From Legend Biotech USA Inc.

Via GlobeNewswire

Johnson & Johnson's Cell Therapy Carvykti Shows Better Survival Rate In Pretreated Blood Cancer Patients ↗

July 02, 2024

Johnson & Johnson announced Phase 3 CARTITUDE-4 study results showing Carvykti significantly improves overall survival in relapsed or lenalidomide-refractory multiple myeloma after one prior line of...

Via Benzinga

Legend Biotech Announces Positive Overall Survival Results of Landmark Phase 3 CARTITUDE-4 Trial in Multiple Myeloma

July 02, 2024

CARVYKTI® demonstrated statistically significant and clinically meaningful improvement in overall survival in second interim analysis

From Legend Biotech USA Inc.

Via GlobeNewswire

Legend Biotech's Cancer Drug, 'The Most Attractive Product,' Set For Growth: Analyst ↗

June 17, 2024

Legend Biotech analyst predicts growth for Carvykti. The Multiple Myeloma drug could become a $5B+ product.

Via Benzinga

Novavax And Agios Pharmaceuticals Were Among The 10 Biggest Mid-Cap Gainers Last Week (June 1-June 7): Are These In Your Portfolio? ↗

June 09, 2024

Mid-cap stocks saw significant gains last week, with top performers like AGIO, VRNT, and NVAX, causing analysts to raise their forecasts.

Via Benzinga

Legend Biotech Shares Data on the Earliest Use to Date of CARVYKTI® in the Treatment of Multiple Myeloma and Important Subgroup Analyses at ASCO and EHA

June 03, 2024

From Legend Biotech

Via Business Wire

Legend Biotech to Participate in the Jefferies Global Healthcare Conference

May 29, 2024

From Legend Biotech Corporation

Via Business Wire

Legend Biotech to Highlight Leadership in CAR-T Cell Therapy for Patients with Multiple Myeloma at ASCO and EHA

May 23, 2024

From Legend Biotech Corporation

Via Business Wire

Amid Biotech Pitfalls, ImmunityBio Has Outperformed NVDA In The Last 3 Months ↗

May 13, 2024

In the last three months, IBRX outperformed NVDA by over 3x.

Via Talk Markets

LEGN Stock Earnings: Legend Biotech Beats EPS, Misses Revenue for Q1 2024 ↗

May 13, 2024

LEGN stock results show that Legend Biotech beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.

Via InvestorPlace

Legend Biotech Reports First Quarter 2024 Results and Recent Highlights

May 13, 2024

From Legend Biotech Corporation

Via Business Wire

CARVYKTI® (ciltacabtagene autoleucel) Approved by the European Commission for Second-line Treatment of Patients with Relapsed and Refractory Multiple Myeloma

April 22, 2024

From Legend Biotech Corporation

Via Business Wire

FDA Mandates "Boxed Warning" For Bristol Myers, Johnson & Johnson CAR-T-Based Blood Cancer Therapies ↗

April 19, 2024

Following an investigation announced in November last year, the FDA said on Thursday that it would now require boxed warnings—the highest safety-rel

Via Benzinga

Legend Biotech to Host Investor Conference Call on First Quarter 2024 Results

April 11, 2024

From Legend Biotech Corporation

Via Business Wire

Johnson & Johnson's Carvykti Stands Ahead Of Bristol Myers' Rival Blood Cancer Therapy With FDA Approval For Wider Population ↗

April 08, 2024

FDA approves Johnson & Johnson's Carvykti, a BCMA-targeted therapy for relapsed or refractory multiple myeloma patients, offering hope with increased manufacturing capacity and extended collaboration...

Via Benzinga

Legend Biotech’s CARVYKTI® (ciltacabtagene autoleucel) Becomes the First and Only BCMA-Targeted CAR-T Cell Therapy Approved by the FDA for Second-Line Treatment of Multiple Myeloma

April 05, 2024

From Legend Biotech Corporation

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 9

...

12 13 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.